Factor Model (net +1.3)
Factor Model
net +1.3 3.1 / 10Barclays lifts target as MCK completes European exit
Watch: Monitor capital allocation announcements over the next two quarters—specifically Oncology and Biopharma Services revenue growth rates relative to guidance. Faster growth in these segments will validate the strategic thesis and justify the premium multiple.
McKesson finished unwinding its European operations in January by selling Norway's retail and distribution businesses to NorgesGruppen, capping a strategic realignment started in August 2025. Barclays responded by raising its price target to $1,050 from $960 on February 18, maintaining an Overweight rating and arguing the stock should stay favored in healthcare as a pocket of safety. The company now frees capital to chase faster-growing Oncology, Multispecialty, and Biopharma Services segments.
The exit clears balance-sheet friction and lets management concentrate firepower on higher-margin healthcare services. Barclays' 9.4% upside raise, coupled with conviction on continued investor preference for defensive healthcare plays, signals confidence that MCK's refocused portfolio and capital deployment will outperform. The 15% valuation premium to the three-year average reflects this renewed momentum.
Evidence
Fundamentals & Data ▾
Recent transactions
Get alerted when MCK changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.